Journal: Cell Death & Disease

Article Title: Regulation of proliferation and cell cycle by protein regulator of cytokinesis 1 in oral squamous cell carcinoma

doi: 10.1038/s41419-018-0618-6

Figure Lengend Snippet: a , e , f After PRC1 knockdown, TβRII and AURKA expression in HSC-2 cells and AURKA expression in Cal-27 cells were unaltered while TβRII was decreased in Cal-27 cells. b , e , f Expression of pho-p53 (Ser 392 ) increased while EGFR decreased significantly following PRC1 knockdown. c , g , h Following activation with Nutlin-3, expression of both p53 and pho-p53 (Ser 392 ) increased while that of PRC1 and EGFR decreased significantly. d , i , j P53 and pho-p53 (Ser 392 ) were inhibited by Pifithrin-α, which in turn initiated an upregulation of both PRC1 and EGFR. All n ≥ 3 ; error bars, mean ± SD; n.s, not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; t -test

Article Snippet: After transferring to the PVDF membrane (Millipore, Darmstadt, Germany), the protein contents were probed with anti-EGFR, TβRII, AURKA and p53, pho-p53 (Ser 392 ) (1:500, ImmunoWay, Plano, TX, USA), and anti-PRC1 (1:5000, Abcam, Cambridge, UK) antibodies, using GAPDH as a control.

Techniques: Knockdown, Expressing, Activation Assay

Journal: Cell Death & Disease

Article Title: Regulation of proliferation and cell cycle by protein regulator of cytokinesis 1 in oral squamous cell carcinoma

doi: 10.1038/s41419-018-0618-6

Figure Lengend Snippet: a In OSCC, inhibition of p53 leads to overexpression of PRC1, which in turn further suppresses p53. The EGFR signaling pathway is enhanced by overexpressed PRC1, subsequently leading to the promotion of proliferation. b After PRC1 knockdown in OSCC, p53 is upregulated which causes additional inhibition of PRC1 as feedback, which consequently suppresses the EGFR pathway and inhibits proliferation

Article Snippet: After transferring to the PVDF membrane (Millipore, Darmstadt, Germany), the protein contents were probed with anti-EGFR, TβRII, AURKA and p53, pho-p53 (Ser 392 ) (1:500, ImmunoWay, Plano, TX, USA), and anti-PRC1 (1:5000, Abcam, Cambridge, UK) antibodies, using GAPDH as a control.

Techniques: Inhibition, Over Expression, Knockdown